Hepatitis Research and Treatment

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection


Publishing date
15 Oct 2010
Status
Published
Submission deadline
15 Apr 2010

Lead Editor

1Department of Gastroenterology, Tokai University School of Medicine, Japan

2Department of Gastroenterology and Hepatology, Stanford University, USA

3Department of Internal Medicine, Kaohsiung Medical University and Hospital, Taiwan


Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection

Description

The combination therapy with pegylated interferon (Peg-IFN) and ribavirin has been accepted as a “standard-of-care” treatment for chronic hepatitis C. However, this therapy is far from satisfactory; the sustained virological response (SVR) is achieved in no more than half of the patients infected with genotype 1. At present, 48-week therapy for genotype 1/4 and 24-week therapy for genotype 2/3 are recommended. Recently, the concept of individualized therapy has emerged; patients with rapid virological response may be successfully treated with shorter course of therapy than scheduled, whereas late responders may require longer course. Further data is required to provide patients with optimal regimens.

Although prognosis of the patients who have obtained SVR is fairly good, long-term efficacy of Peg-IFN maintenance therapy aiming the suppression of viral replication for those who could not eradicate virus by the standard-of-care therapy is still controversial. More information whether Peg-IFN maintenance therapy suppresses the progression to liver cirrhosis or hepatocellular carcinoma is required.

We have to wait for a while until the specifically targeted antiviral therapy for HCV (STAT-C) agents is launched in the market. Even after the appearance of STAT-C agents, Peg-IFN and ribavirin may remain as the mainstay in the treatment for chronic hepatitis C.

In this special issue, we are focusing on these unsolved problems in the Peg-IFN/ribavirin combination therapy for chronic hepatitis C.

The topics to be covered include, but are not limited to:

  • Factors associated with SVR
  • Response-guided therapy
  • Difference between Peg-IFN alfa-2a and alfa-2b
  • Treatment of difficult-to-cure patients
  • Treatment of special groups of patients (patients with renal failure, liver transplant recipients, etc.)
  • Long-term effect of IFN treatment on the progression of liver diseases
  • New IFNs (e.g., albuferon) and alternative forms of ribavirin (e.g., viramidine)

Before submission, authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/heprt/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2010
  • - Article ID 275274
  • - Editorial

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection

Tatehiro Kagawa | Emmet B. Keeffe | Ming-Lung Yu
  • Special Issue
  • - Volume 2010
  • - Article ID 475746
  • - Review Article

Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation

Yasuhiko Sugawara | Sumihito Tamura | Norihiro Kokudo
  • Special Issue
  • - Volume 2010
  • - Article ID 537827
  • - Clinical Study

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Douglas F. Meyer | Hillel Tobias | ... | Henry C. Bodenheimer
  • Special Issue
  • - Volume 2010
  • - Article ID 140953
  • - Review Article

Evolution of Interferon-Based Therapy for Chronic Hepatitis C

Chun-Hao Chen | Ming-Lung Yu
  • Special Issue
  • - Volume 2010
  • - Article ID 562578
  • - Review Article

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C

Tatehiro Kagawa | Emmet B. Keeffe
  • Special Issue
  • - Volume 2010
  • - Article ID 267412
  • - Research Article

Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update

Hugo Weclawiak | Nassim Kamar | ... | Lionel Rostaing
  • Special Issue
  • - Volume 2010
  • - Article ID 495928
  • - Clinical Study

Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection

Rie Kubota | Takako Komiyama | ... | Kanji Tsuchimoto
  • Special Issue
  • - Volume 2010
  • - Article ID 323926
  • - Review Article

Treatment of Hepatitis C Infections with Interferon: A Historical Perspective

Robert M. Friedman | Sara Contente
  • Special Issue
  • - Volume 2010
  • - Article ID 703602
  • - Review Article

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

Namiki Izumi | Yasuhiro Asahina | Masayuki Kurosaki
  • Special Issue
  • - Volume 2010
  • - Article ID 961359
  • - Review Article

Hepatitis C in Haematological Patients

Y. Y. Hwang | R. H. S. Liang

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.